Skip to main content
Premium Trial:

Request an Annual Quote

Eone-Diagnomics, Cordlife Ink NIPT Deal

NEW YORK (GenomeWeb) – Eone-Diagnomics Genome Center (EDGC) announced today that it has signed an agreement to offer its Gen Screen non-invasive prenatal test in certain Asian markets in partnership with cord blood service provider Cordlife.

Under the terms of the deal, EDGC — joint venture between San Diego-based bioinformatics firm Diagnomics and South Korea's Eone Life Science Institute — will service the test in the Philippines and Indonesia through Singapore-based Cordlife's sales networks in those nations. EDGC said it anticipates expanding the relationship later to include additional Asian countries and its other products such as the DTC genetic test Gene2me and the ophthalmology genetic test Myeyegene.

Additional terms were not disclosed.

Earlier this year, EDGC partnered with Chinese genetic analysis company GPBio to develop and expand consumer and clinical genomic services for Asian markets.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.